Regeneron Pharmaceuticals (REGN) Could Be 5% Undervalued Following Fresh Libtayo Phase 3 Data

Regeneron Pharmaceuticals (REGN) is back in focus after late-breaking C POST Phase 3 data at ESMO 2026 showed sustained disease-free survival and emerging overall survival benefits for Libtayo in high-risk CSCC.

That clinical backdrop sits alongside a share price that has climbed over the past year, with Regeneron Pharmaceuticals delivering a 15.8% 90-day share price return and a 38.24% 1-year total shareholder return, although the stock slipped 1.72% on the day of the latest Libtayo update.

Scan for other oncology-focused stories with similar clinical momentum by reviewing the hand-picked 34 healthcare AI stocks that could also be reshaping treatment outcomes and investor expectations.

Regeneron Pharmaceuticals now couples fresh Libtayo data with a strong 1-year share run. After that kind of move, does the current price still compensate you for the clinical and pipeline risk on the table?

Most Popular Narrative: 5.4% Undervalued

Against a last close of $805.02, the most followed narrative places Regeneron Pharmaceuticals' fair value at about $850.88. This points to a modest gap that hinges on how investors weigh Dupixent, EYLEA HD, and the pipeline beyond Libtayo.

Regeneron Pharmaceuticals is still advancing a broad late stage pipeline in areas such as immunology, oncology, genetic medicines, and obesity. Continued readouts and regulatory decisions on these programs can add new revenue streams that support earnings growth beyond the current product portfolio.

See why 87 investors see Regeneron Pharmaceuticals as 5% undervalued.

Result: Fair Value of $850.88 (UNDERVALUED)

Still, the Regeneron Pharmaceuticals story can flip if EYLEA HD faces sharper pressure from rivals like Zenkuda, or if Libtayo related litigation escalates.

Find out about the key risks to this Regeneron Pharmaceuticals narrative.

Next Steps

If sentiment around Regeneron Pharmaceuticals feels divided, that is the point. Review the underlying numbers now and form your own stance using the 3 key rewards.

Looking for more investment ideas beyond Regeneron Pharmaceuticals?

You have seen how one ticker can shift quickly. Cast the net wider now and let the screener surface ideas you might otherwise miss.

• Target quality at a discount by scanning companies that look mispriced on fundamentals using the 28 high quality undervalued stocks.
• Prioritise resilience by reviewing a list of solid balance sheet and fundamentals (24 results) that can better handle shocks without constant refinancing risk.
• Get ahead of the crowd by tracking 21 high quality undiscovered gems before they sit on every analyst’s radar.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com